Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kwang-Wei Wu"'
Autor:
Shih-Pei Shen, Hsin-An Hou, Kuan-Chih Huang, Choo Hua Goh, Hong Qiu, Lee Anne Rothwell, Kwang-Wei Wu, Hitesh Chandwani, Yanfang Liu, Chao-Hsiun Tang
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract We conducted a retrospective population-based, matched cohort study using the National Health Insurance Research Database to estimate healthcare resource utilisation (HRU) and costs in patients with newly diagnosed AL amyloidosis in Taiwan.
Externí odkaz:
https://doaj.org/article/ea43d093726f4b27aa619021ef7adf4d
Autor:
Andrew Spencer, Olga Samoilova, Wee‐Joo Chng, Richard Labotka, Cong Li, Kwang‐Wei Wu, Nakul Saxena, Xu Yan, Jae Hoon Lee, Meral Beksac
Publikováno v:
eJHaem, Vol 3, Iss 4, Pp 1241-1251 (2022)
Abstract Ixazomib‐lenalidomide‐dexamethasone (ixazomib‐Rd) showed clinical efficacy over placebo‐Rd in patients with relapsed/refractory multiple myeloma (MM) in the TOURMALINE‐MM1 trial. Over a median follow‐up of ∼85 months, as patien
Externí odkaz:
https://doaj.org/article/ac5e08cef8eb4d8db5c4c2f0bd81a0d0
Autor:
Mubarak Al-Mansour, Yok-Lam Kwong, Soon Thye Lim, Tae Min Kim, Amado Karduss, Su-Peng Yeh, Kwang-Wei Wu, Burhan Ferhanoglu, Marta Zerga, Mark Hertzberg, Silvia Rivas-Vera, Zhongwen Huang, Gayane Tumyan, Yuqin Song
Publikováno v:
Blood. 138:1397-1397
Background: Positron emission tomography-computed tomography (PET-CT) is used for staging and response assessment in classical Hodgkin lymphoma (cHL) and for evaluation and management of refractory/relapsed Hodgkin lymphoma (RRHL). According to the W
Autor:
Wenming Chen, Wee Joo Chng, Hui Wan, Fahad Alsharif, Tatiana Mitina, Meral Beksac, Kihyun Kim, Su-Peng Yeh, Zijing Zhang, Estelle Verburgh, Kwang-Wei Wu, Dorotea Fantl
Publikováno v:
Blood. 134:5577-5577
Introduction The incidence of multiple myeloma (MM) has increased globally in the past decade and is predicted to increase in developing countries due to ageing populations and improvements in diagnosis. Studies outlining the relationship between lon
Autor:
MaoFang Lin, LinNa Wang, Yu-hong Zhou, Wenming Chen, Zhi-Xiang Shen, Taiyun Zhao, Zhuogang Liu, Jian Hou, Xiao-Jun Huang, Kwang-Wei Wu, Yan Li
Publikováno v:
Advances in Therapy
Introduction Bortezomib, a novel proteasome inhibitor, is approved for the treatment of relapsed multiple myeloma (MM). Efficacy and safety of bortezomib is well known; however, it was necessary to validate the data in patients with different ethnic
Autor:
Yan Xu, Yeow Tee Goh, Kwang-Wei Wu, Jae Hoon Lee, Hui Wang, Xiaoyan Ke, Xin Du, Kihyun Kim, Jie Jin, Weijun Fu, Depei Wu, Hui Wan, Deborah Berg, Tomas Skacel, Wee Joo Chng, Xiequn Chen, Guohui Liu, Jing Liu, Junmin Li, Daobin Zhou, Jin Lu
Publikováno v:
Blood. 132:5637-5637
Introduction: Ixazomib (Ninlaro) is the first orally administered proteasome inhibitor (PI) approved in more than 50 countries worldwide, including China. The TOURMALINE-MM1 study was a large randomized, double-blind, global registration study assess